“We’re combating the pathogens
of today and tomorrow”


The Impact of Hospital Acquired Infections

  • At any given time, about 1 in 31 US patients will contract at least one infection during a hospital stay.
  • An estimated 1.7 million infections and nearly 70,000 associated deaths each year
  • Bacteria alone cause about 90% of HAIs
  • US hospitals spend $45 billion each year treating HAIs
  • Cleaning practices decontaminate only 50% of problem surfaces


NuvaWave has a critical role to play in ensuring the integrity of the places we trust to help us stay well and healthy, not just during this time of COVID, but always.
The Texas Biomedical Research Institute recently completed an independent testing on the efficacy of NuvaWave in killing SARS-CoV-2. They demonstrated that NuvaWave killed 99.98% of the virus in 2 seconds. No other UV device in the world has demonstrated these types of results with an independent 3rd party.
Hospitals must be continually cleaned to remain safe. Every hour after a terminal clean the bioburden of a hospital room increases, creating a gap for pathogens to grow and endanger patients.

3rd Party Testing Results

NuvaWave® is engineered to deliver the best performance on the market. That means shorter cycles, higher efficacy, and safer spaces than competitors. Efficacy testing shows that NuvaWave® can destroy over 99.98% of the most common and harmful pathogens in just 1 second.


99.88% in 1 second


MRSA (Methicillin-Resistant Staphylococcus Aureus)

99.75% in 1 second

Acinetobacter baumannii

Acinetobacter baumannii

99.93% in 1 second

Escherichia coli

Escherichia coli

99.999% in 1 second

Enterococci Faecalis

Enterococci Faecalis

99.96% in 1 second


Klebsiella pneumoniae

99.64% in 1 second



99.95% in 1 second

Pseudomonas aeruginosa

Pseudomonas aeruginosa

99.9% in 1 second

Download The
NuvaWave® Pathogen Research Summary